Dr. Rashem Mothilal, General Manager of Dr. Reddy’s Laboratories South Africa.
A new immunotherapy has been registered in South Africa for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare and aggressive form of head and neck cancer.
According to the Cancer Association of South Africa (CANSA), it is estimated that 1 in 7 South African males and 1 in 8 South African females will be diagnosed with cancer during their lifetime. While awareness campaigns have helped many recognise the warning signs of breast, prostate and lung cancer, hundreds of rare cancers continue to go largely unnoticed; often because their symptoms resemble everyday illnesses that people experience without a second thought.
The announcement of the new immunotherapy registration was made by Dr Reddy’s Laboratories South Africa.
According to the organisation, the registration marks an important step forward in expanding access to modern cancer treatments for patients living with the rare disease.
